ニュース、リソース、最新情報
当社の最新の研究動向や企業情報をお届けする科学情報拠点です。
ADPKDマウスモデルにおける標的遺伝子治療の非臨床試験アプローチ
近年、遺伝子治療が相次いで承認され、さらに多くの承認が控える中、希少遺伝性疾患の分野は変革期を迎えている。ADPKDを含む希少遺伝性腎疾患の分野も例外ではなく、遺伝子治療が新たな治療法として台頭しつつある...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
マウスデータを用いたPK/PD関係の確立による前臨床研究の推進方法
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
InnoSer International Announces Leadership Transition: Kris Motmans Appointed as New CEO
Diepenbeek, Belgium, Feb 17, 2025 — InnoSer International, a leading preclinical Contract Research Organization (CRO) specializing in innovative solutions for drug development, proudly announces the appointment of Kris Motmans as the new Chief Executive Officer. This...
MDX Mouse Model Validation Data
This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD. The X-linked muscular dystrophy (MDX)...
膵臓癌患者由来異種移植モデル
先月11月は膵臓がん啓発月間でした。これは最も攻撃的で致死率の高いがん種の一つがもたらす課題に焦点を当てる時期です。膵臓がんは欧州で診断される全がんの約3％を占め、膵臓...
info@innoserlaboratories.com